Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome

BMC Infectious Diseases

Kuender-D Yang⁴  Rong-Fu Chen⁴  Chia-Chi Chang¹  Jien-Wei Liu³  Lin-Hui Su²  Chen-Hsiang Lee³ 

[1] Division of Infectious Diseases, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan;Chang Gung University, College of Medicine, Kweishan, Taoyuan, Taiwan;Chang Gung University College of Medicine, Kaohsiung, Taiwan;Department of Medical Research, Show Chwan Memorial Hospital, 6 Lukong Road, Lugang, Changhua 505, Taiwan

关键词: Invasive syndrome;    Phagocytosis;    Hypermucoviscosity;    K. pneumoniae;    Salicylate;   

Others  :  1134879
DOI  :  10.1186/1471-2334-14-47

 received in 2013-10-23, accepted in 2014-01-23,  发布年份 2014

【 摘 要 】

Background

Klebsiella pneumoniae (KP) expressing hypermucoviscosity phenotype (HV-KP) has abundant capsular polysaccharide (CPS) and is capable of causing invasive syndrome. Sodium salicylate (SAL) reduces the production of CPS. The study was aimed to investigate the relationship between aspirin usage and KP-mediated invasive syndrome and the effect of SAL on HV-KP.

Methods

Patients with community-acquired KP bacteraemia were prospectively enrolled. KP-M1, a serotype-K1 HV-KP clinical isolate, was used in the following experiments: CPS production, HV-KP phenotype, and the effect of SAL on neutrophils phagocytosis. The effect of oral aspirin intake on the leukocyte bactericidal activity was evaluated.

Results

Patients infected by HV-KP and diabetic patients with poor glycemic control were at an increased risk for invasive syndrome (p < 0.01); those who had recent use of aspirin (p = 0.02) were at a lower risk. CPS production was significantly reduced in the presence of SAL. The HV-KP phenotype and resistance to neutrophil phagocytosis were both significantly reduced in the KP-M1 after incubation with SAL (p < 0.01). Aspirin treatment significantly enhanced the killing of KP-M1 by leukocytes (p < 0.01).

Conclusion

Treatment with SAL significantly reduces CPS production in HV-KP, thereby contributing to leukocyte phagocytosis and bactericidal activity against this pathogen.

【 授权许可】

   
2014 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wann SR, Lin HH: Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis 1998, 26:1434-1438.
• [2]Ko WC, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, McCormack JG, Yu VL: Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002, 8:160-166.
• [3]Lee CH, Liu JW, Su LH, Chien CC, Li CC, Yang KD: Hypermucoviscosity associated with Klebsiella pneumoniae-mediated invasive syndrome: a prospective cross-sectional study in Taiwan. Int J Infect Dis 2010, 14:e688-e692.
• [4]Lin JC, Chang FY, Fung CP, Xu JZ, Cheng HP, Wang JJ, Huang LY, Siu LK: High prevalence of phagocytic-resistant capsular serotypes of Klebsiella pneumoniae in liver abscess. Microbes Infect 2004, 6:1191-1198.
• [5]Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, Chen CT, Wang SC, Chang FY: Impaired phagocytosis of capsular serotype K1 or K2 Klebsiella pneumoniae in type 2 diabetic mellitus patients with poor glycemic control. J Clin Endocrinol Metab 2006, 91:3084-3087.
• [6]Lin JC, Chang FY, Fung CP, Yeh KM, Chen CT, Tasi YK, Siu LK: Do neutrophils play a role in establishing liver abscesses and distant metastases caused by Klebsiella pneumoniae. PLoS One 2010, 5:e15005.
• [7]Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC: Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis 2007, 45:284-293.
• [8]Pollack M: Significance of circulating capsular antigen in Klebsiella infections. Infect Immun 1976, 13:1543-1548.
• [9]Domenico P, Schwartz S, Cunha BA: Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 1989, 57:3778-3782.
• [10]Domenico P, Salo RJ, Straus DC, Hutson JC, Cunha BA: Salicylate or bismuth salts enhance opsonophagocytosis of Klebsiella pneumoniae. Infection 1992, 20:66-72.
• [11]Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
• [12]Aronoff DM, Lewis C, Serezani CH, Eaton KA, Goel D, Phipps JC, Peters-Golden M, Mancuso P: E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection. J Immunol 2009, 183:2642-2649.
• [13]Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, Gilroy DW: Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 2010, 116:2950-2959.
• [14]American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
• [15]Yu VL, Hansen DS, Ko WC, Sagnimeni A, Klugman KP, von Gottberg A, Goossens H, Wagener MM, Benedi VJ, International Klebseilla Study Group: Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007, 13:986-993.
• [16]American Diabetes Association: Standards of medical care in diabetes-2009. Diabetes Care 2009, 32:S13-S61.
• [17]Lee HC, Chuang YC, Yu WL, Lee NY, Chang CM, Ko NY, Wang LR, Ko WC: Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteremia. J Intern Med 2006, 259:606-614.
• [18]Bitter T, Muir HM: A modified uronic acid carbazole reaction. Anal Biochem 1962, 4:330-334.
• [19]Domenico P, Diedrich DL, Cunha BA: Quantitative extraction and purification of exopolysaccharides from Klebsiella pneumoniae. J Microbiol Methods 1989, 9:211-219.
• [20]Heinzelmann M, Gardner SA, Mercer-Jones M, Roll AJ, Polk HC Jr: Quantification of phagocytosis in human neutrophils by flow cytometry. Microbiol Immunol 1999, 43:505-512.
• [21]Hampton MB, Vissers MC, Winterbourn CC: A single assay for measuring the rates of phagocytosis and bacterial killing by neutrophils. J Leukoc Biol 1994, 55:147-152.
• [22]Green JN, Winterbourn CC, Hampton MB: Analysis of neutrophil bactericidal activity. Methods Mol Biol 2007, 412:319-332.
• [23]Williams P, Lambert PA, Haigh CG, Brown MR: The influence of the O and K antigens of Klebsiella aerogenes on surface hydrophobicity and susceptibility to phagocytosis and antimicrobial agents. J Med Microbiol 1986, 21:125-132.
• [24]Domenico P, Diedrich DL, Straus DC: Extracellular polysaccharide production by Klebsiella pneumoniae and its relationship to virulence. Can J Microbiol 1985, 31:472-478.
• [25]Cerletti C, Dell’Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003, 42:1059-1070.
• [26]Fung CP, Lin YT, Lin JC, Chen TL, Yeh KM, Chang FY, Chuang HC, Wu HS, Tseng CP, Siu LK: Klebsiella pneumoniae in gastrointestinal tract and pyogenic liver abscess. Emerg Infect Dis 2012, 18:1322-1325.
• [27]Sutherland IW: Bacterial polysaccharides—their nature and production. In Surface carbohydrates of the prokaryotic cell. Edited by Sutherland IW. New York: Academic Press; 1977:27-96.
• [28]Leive L: Studies on the permeability change produced in coliform bacteria by ethylenediamine tetraacetate. J Biol Chem 1968, 243:2373-2380.
• [29]Salo RJ, Domenico P, Tomás JM, Straus DC, Merino S, Benedí VJ, Cunha BA: Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components. Infection 1985, 23:371-377.